Bamboat Zubin M, Dematteo Ronald P
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Surg Oncol Clin N Am. 2012 Apr;21(2):301-16. doi: 10.1016/j.soc.2011.12.004.
Despite being the most common sarcoma of the gastrointestinal tract, gastrointestinal stromal tumor (GIST) has been widely recognized as a unique entity for just over a decade. The advent of tyrosine kinase inhibitors has revolutionized the diagnosis and treatment of GIST. Although surgery remains the only chance for cure, multimodal treatment that includes molecular therapy continues to develop. Optimal management of GIST requires careful radiographic, pathologic, medical, and surgical care, emphasizing the need for a multidisciplinary approach. This review highlights recent developments in the management of GIST.
尽管胃肠道间质瘤(GIST)是胃肠道最常见的肉瘤,但在仅仅十多年的时间里,它已被广泛公认为一种独特的疾病实体。酪氨酸激酶抑制剂的出现彻底改变了GIST的诊断和治疗方式。虽然手术仍然是治愈的唯一机会,但包括分子治疗在内的多模式治疗仍在不断发展。GIST的最佳管理需要仔细的影像学、病理学、医学和手术护理,强调了多学科方法的必要性。本综述重点介绍了GIST管理方面的最新进展。